Case fatality rate of the adult in-patients with COVID-19 and digestive system tumors
A systematic review and meta-analysis
Guoqun Wang, MMA, Lanlan Pan, MMDB, Jianyi Zhao, BSBC, Jie Tang, MMD, Yueyu Fang, MMc, Hui Sun, MMd, Poshita Kumari Seesaha, MMSc, Wensen Chen, PhDe, Xiaofeng Chen, PhDb,∗

Abstract
Background: During the coronavirus disease 2019 (COVID-19) pandemic, endoscopic screening for gastrointestinal tumors was suspended or delayed in most countries. Thus, our study aimed to quantify the impact of COVID-19 on the clinical outcomes of patients with digestive system tumors through a systematic review and meta-analysis.

Methods: We systematically searched the PubMed, Web of Science, Cochrane Library, and Embase databases as of March 7, 2021 to identify the case fatality rate (CFR) of COVID-19 patients diagnosed with digestive system tumors. A random-effects model was used for meta-analysis, I2 was used to assess heterogeneity, and funnel plot was used to assess publication bias.

Results: A total of 13 studies were included, involving 2943 tumor patients with COVID-19, of which 871 were digestive system tumors, and the CFR was 24% (95% CI, 18%–30%; I2 = 55.7%). The mortality rate of colorectal cancer was 21% (95% CI, 14%–27%); I2 = 0.0%), gastric cancer was 25% (95% CI, 6%–45%; I2 = 0.0%), and hepatobiliary cancer was 29%. In general, there was no significant difference in the CFR of digestive system tumors.

Conclusion: The combined CFR of digestive system tumors and COVID-19 patients was 24%, which is much higher than that of the general population. Under the premise of fully complying with the international guidelines to limit the spread of COVID-19, we call for the resumption of endoscopic screening programs and selective surgery as soon as possible.

Registration information: PROSPERO registration no. CRD42021248194.

Abbreviations: ACE-2 = angiotensin-converting enzyme-2, CFR = the case fatality rate, CI = confidence interval, COVID-19 = the coronavirus disease 2019, CTC = computed tomography colonography, CTSL = cathepsin L, ES = effect size, FIT = fecal immunochemical test, ICU = intensive care unit, NOS = Newcastle-Ottawa Scale, OR = odds ratio, PRISMA = Preferred reporting items for systematic reviews and meta-analyses, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, SD = standard deviation, TMPRSS2 = transmembrane protease serine 2, WHO = the World Health Organization.

Keywords: case fatality rate, COVID-19, digestive system tumors, mortality, SARS-CoV-2, systematic review and meta-analysis
1. Introduction

COVID-19 is a new respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On March 11, 2020, the World Health Organization (WHO) announced that COVID-19 was a global pandemic, and it has now been constituted a public health emergency of international concern. According to the real-time statistics of the global COVID-19 epidemic, as of February 14, 2022, more than 412 million COVID-19 cases have been confirmed worldwide, and the cumulative number of deaths has reached 5.83 million. Compared with the general population, cancer patients are more susceptible to COVID-19. Liang et al observed that COVID-19 patients with cancer have a higher risk and frequency of serious events compared with those who have no cancer. In addition to the fact that the tumor itself and the anti-tumor treatment will directly lead to the damage of the immune system, the overall age of tumor patients is older and they also have coexisting multiple comorbidities, which may be potential risk factors for an increased risk of COVID-19 infection and poor prognosis.

Due to the COVID-19 pandemic, endoscopic screening has been suspended or delayed in most countries, causing the diagnostic rate of digestive system tumors to drop to half. A delay in the endoscopic diagnosis of colorectal cancer in patients with positive clinical manifestations, including positive fecal occult blood tests and suspicious radiological findings, will increase the risk of tumor progression and metastasis. Even if screening is resumed, the impact of this delay on disease progression is still irreversible. In addition, some studies have found that there are coronavirus-like particles in the cytoplasm or surface of intestinal cells in the appendix, colon, or rectum of some patients with COVID-19, indicating that the virus productively infects human gut enterocytes. Therefore, it is imperative to conduct a comprehensive assessment of patients with digestive system tumors on the premise of complying with the guidelines for prevention and control of the epidemic situation of COVID-19.

Here, we conducted a systematic review and meta-analysis of patients with digestive system tumors infected with COVID-19 to assess the overall mortality rate and potential risk factors of this population and provide a reference for the clinical treatment of cancer patients under the background of the COVID-19 pandemic.

2. Methods

2.1. Search strategy

We conducted a systematic search of four databases, namely PubMed, Web of Science, Cochrane Library, and Embase. Combining MeSH terms and keyword strategies, we used the following search terms: [(COVID-19) OR [coronavirus-disease-19] OR [novel coronavirus] OR [new coronavirus] OR 2019 novel coronavirus) OR (2019-nCoV) OR (nCoV-2019) OR (novel coronavirus) OR (novel coronavirus pneumonia) OR (coronavirus disease 2019) OR (severe acute respiratory syndrome coronavirus 2) OR (SARS-CoV-2) AND [(cancer] OR [neoplasm] OR [oncology] OR [malignancy] OR [tumor] OR [cancer])]. Considering the time of the COVID-19 outbreak, the publication date was limited from December 2019 to March 7, 2021. We pre-specified the search results for studies written in or translated into English. There were 10,727 articles in total. In addition, we manually searched the references of the selected articles to obtain all possible relevant studies. Our report was based on the PRISMA statement of systematic reviews and meta-analyses. EndNote X9 software was used to manage the records and eliminate duplicates. This research proposal was submitted to the PROSPERO database (CRD42021248194) for registration and approved by the Medical Ethics Committee of Nanjing Pukou Central Hospital (NPEC-2020-019).

2.2. Article selection

After eliminating duplicate data, two authors (GW, LP) independently extracted all eligible studies and determined their final eligibility based on the inclusion and exclusion criteria. Only original research articles meeting the following criteria were included in the study:

1. Included patients who had been diagnosed with cancer and subsequently confirmed to be infected with COVID-19 by the laboratory;
2. Study type was original research article;
3. The clinical characteristics and outcome information of the patients were reported.

The exclusion criteria were as follows:

1. Non-original research (reviews, clinical guidelines, expert consensus, letters, plans, news, or comments);
2. Research on the death outcome of cancer patients infected with COVID-19 was not reported;
3. Animal research;
4. Molecular biology research;
5. Case report;
6. Clinical trials;
7. Research where the data is incomplete or the full text cannot be retrieved; and,
8. Research where the research object is medical staff.

In cases of studies with overlapping data, the study with a larger sample size was used.

2.3. Data extraction

Two authors (LP and JZ) screened and extracted the data according to the pre-designed form of the Excel spreadsheet. All differences were resolved by consensus and further adjudicated by a third author (WC). The extracted information included the first author, publication time, study design, cohort name, study period, single/multi center, country, region, cancer patients with COVID-19, median age, male percentage, percentage of patients in the intensive care unit (ICU), proportion of severe cases, percentage of patients with ventilator support, comorbidities, therapy, cancer stage, tumor type, and clinical outcome.

2.4. Literature quality evaluation

The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of the included studies. Based on the scores, the risk of bias in the studies were categorized into low (7–9), moderate (4–6), and high (1–3).

2.5. Data analysis

The data are presented as mean and standard deviation (SD) for numerical data, and proportions for categorical data. The CFR...
was defined as the number of patients with cancer who died divided by the number of patients with a known hospital outcome (death or discharged alive) after the diagnosis of COVID-19. The results are presented as forest plots. Chi-square test and $I^2$ statistics were used to assess the heterogeneity of the results (25%, 50%, and 75% represent low, moderate, and high heterogeneity, respectively). If $P > .1$ and $I^2 < 50\%$, a fixed-effects model was used for meta-analysis; otherwise, a random-effects model was used for meta-analysis. We used a random-effects model to calculate the CFR of patients with digestive tract tumors infected with COVID-19. Publication bias was assessed using funnel plot. Odds ratio (OR) was used to measure the strength of association, while a 95% confidence interval (CI) was used to measure the accuracy of estimation. Stata/SE 15.1 for Windows (College Station, TX) was used for data analysis.

3. Results

3.1. Literature search

The flow diagram in Figure 1 shows the detailed literature search steps. Through comprehensive literature retrieval, we retrieved 10,723 articles from PubMed, Web of Science, Cochrane Library, and EMBASE, and four additional records identified through other sources. After excluding duplicate documents, 4753 articles were screened by title and abstract, and 525 full-text articles were assessed for eligibility. According to our inclusion and exclusion criteria, 472 articles were excluded, and 53 articles were included in the qualitative review. Forty articles were excluded because they did not report the death outcome of patients with digestive system tumors. Finally, 13 articles were included in the meta-analysis, [8,10–21] one of which was a prospective cohort study, and the rest were retrospective cohort studies.

3.2. Study characteristics and quality evaluation

We analyzed the data from six countries (China 6, UK 1, USA 1, Japan 1, Italy 2, France 1) and an international cohort study. A total of 2943 patients with COVID-19 were enrolled, including 871 patients with digestive system cancer. The digestive system tumors in the studies refer to tumors that originated in the esophagus, stomach, duodenum, jejunum, ileum, appendix, colon and rectum, liver, biliary tract, pancreas, etc. The pathological types include cancer, sarcoma, and neuroendocrine tumors. The sample size of each study ranged from 6 to 1289, while the sample size of digestive system tumors ranged from 2 to 470, and the CFR ranged from 0% to 100.00%. The median age
tumors was 24% (95% CI, 18%–30%; $I^2 = 55.7%$), which was obtained through a random effects meta-analysis. In contrast, the mortality rate of patients with non-digestive system tumors in the included 13 studies. The overall mortality rate was 24% (95% CI, 18%–30%; $I^2 = 80.2%$). A forest plot is shown in Figure 2.

Next, we assessed whether there was a relationship between the tumor location and prognosis. We divided the studies that reported mortality from tumors of the digestive tract in different locations into appropriate subgroups. The results (Fig. 3) show that the CFR of colorectal cancer, gastric cancer, and hepatobiliary tumors were 21% (95% CI, 14%–27%; $I^2 = 0.0%$), 23% (95% CI, 6%–45%; $I^2 = 0.0%$), and 29% (95% CI, –5% to 62%), respectively. In addition, pancreatic cancer patients had the highest mortality rate, 67% (95% CI, 13%–120%), while esophageal cancer patients had the lowest mortality rate of approximately 17% (95% CI, –13% to 46%). Due to the limited data collected on pancreatic, hepatobiliary, and esophageal tumors in the studies we included, the CFR of these tumors may not have a clear reference value, but the data may be updated in the future for further research. In general, there was no significant difference in the CFR among the different parts of the digestive tract tumors.

When these studies were divided into subgroups according to single/multicenter studies, the CFR of the single-center study group was 25% (95% CI, 17%–33%; $I^2 = 71.5%$) and the multicenter group was 24% (95% CI, 17%–30%; $I^2 = 5.0%$) (Fig. 4). We then conducted a subgroup analysis of the study design and found that the CFR of the retrospective study group was 23% (95% CI, 16%–30%; $I^2 = 59.9%$), while the CFR of the prospective study group was 28% (95% CI, 21%–35%) (Fig. 5). Overall, there was little difference in mortality between the single/multicenter and retrospective/prospective subgroups.
### Table 2
The Newcastle-Ottawa Scale scores of the selected studies in the systematic review.

| Reference | Author      | Exposed cohort | Non-exposed cohort | Ascertainment of exposure | Outcome of interest | Comparability | Assessment of outcome | Length of follow-up | Adequacy of follow-up | Total |
|-----------|-------------|----------------|--------------------|---------------------------|---------------------|---------------|-----------------------|-------------------|----------------------|-------|
| 10        | Yang KY     | 1              | 1                  | 1                         | 1                   | 0             | 1                     | 0                 | 1                    | 6     |
| 11        | Lee LYW     | 1              | 1                  | 1                         | 1                   | 0             | 1                     | 0                 | 0                    | 6     |
| 8         | Liu YL      | 1              | 1                  | 1                         | 1                   | 1             | 1                     | 0                 | 1                    | 7     |
| 12        | Mehta V     | 1              | 1                  | 1                         | 0                   | 1             | 1                     | 0                 | 0                    | 5     |
| 13        | Yang F      | 1              | 1                  | 1                         | 0                   | 0             | 1                     | 0                 | 0                    | 4     |
| 14        | Pinto C     | 1              | 1                  | 1                         | 1                   | 0             | 1                     | 0                 | 0                    | 5     |
| 15        | Lie'vre A   | 1              | 0                  | 1                         | 1                   | 0             | 1                     | 0                 | 0                    | 4     |
| 16        | Dai MY      | 1              | 1                  | 1                         | 1                   | 1             | 1                     | 0                 | 1                    | 7     |
| 17        | Zhang HY    | 1              | 0                  | 1                         | 1                   | 0             | 1                     | 1                 | 1                    | 6     |
| 18        | Stroppa EM  | 1              | 0                  | 1                         | 1                   | 0             | 1                     | 1                 | 1                    | 6     |
| 19        | Bhangu MA   | 1              | 1                  | 1                         | 1                   | 0             | 1                     | 1                 | 0                    | 6     |
| 20        | Yu J        | 1              | 0                  | 1                         | 1                   | 0             | 1                     | 0                 | 1                    | 5     |
| 21        | Nakamura S  | 1              | 0                  | 1                         | 1                   | 0             | 1                     | 1                 | 1                    | 6     |

Based on the scores, the risk of bias in the studies were categorized into low (7–9), moderate (4–6), and high (1–3).

---

**Figure 2.** Forest plot of the CFR of digestive system tumors and non-digestive system tumors with COVID-19. CFR = the case fatality rate, COVID-19 = the coronavirus disease 2019.
### Figure 3

Forest plot of the CFR of digestive tract tumors in different locations with COVID-19. CFR = the case fatality rate, COVID-19 = the coronavirus disease 2019.

| Study ID | ES (95% CI)     | Weight |
|----------|-----------------|--------|
| Colorectal cancer | 0.21 (0.06, 0.37) | 15.04 |
| Liu YL (2020) | 0.20 (-0.15, 0.55) | 2.83 |
| Mehta V (2020) | 0.38 (0.17, 0.59) | 8.06 |
| Dai MY (2020) | 0.11 (-0.99, 0.32) | 8.24 |
| Bhangu MA (2020) | 0.19 (0.10, 0.28) | 45.43 |
| Nakamura S (2020) | 0.20 (-0.15, 0.55) | 2.83 |
| Subtotal (I-squared = 0.0%, p = 0.600) | 0.21 (0.14, 0.27) | 82.43 |
| Gastric cancer | 0.25 (0.01, 0.49) | 5.79 |
| Yang KY (2020) | 0.50 (-0.19, 1.19) | 0.72 |
| Nakamura S (2020) | 0.20 (-0.15, 0.55) | 2.83 |
| Subtotal (I-squared = 0.0%, p = 0.750) | 0.25 (0.06, 0.45) | 9.34 |
| Pancreatic cancer | 0.67 (0.13, 1.20) | 1.22 |
| Mehta V (2020) | 0.67 (0.13, 1.20) | 1.22 |
| Subtotal (I-squared = 0.0%, p = 0.000) | 0.67 (0.13, 1.20) | 1.22 |
| Hepatobiliary cancer | 0.29 (-0.05, 0.62) | 3.10 |
| Mehta V (2020) | 0.29 (-0.05, 0.62) | 3.10 |
| Subtotal (I-squared = 0.0%, p = 0.000) | 0.29 (-0.05, 0.62) | 3.10 |
| Esophageal cancer | 0.17 (-0.13, 0.46) | 3.91 |
| Dai MY (2020) | 0.17 (-0.13, 0.46) | 3.91 |
| Subtotal (I-squared = 0.0%, p = 0.000) | 0.17 (-0.13, 0.46) | 3.91 |
| Heterogeneity between groups: p = 0.520 | Overall (I-squared = 0.0%, p = 0.760) | 0.22 (0.16, 0.28) | 100.00 |

### Figure 4

Forest plot of CFR for single/multicenter study subgroup analysis of digestive system tumors with COVID-19. CFR = the case fatality rate, COVID-19 = the coronavirus disease 2019.

| Study ID | ES (95% CI)     | Weight |
|----------|-----------------|--------|
| Single-center | Yang KY (2020) | 0.22 (0.10, 0.35) | 9.16 |
| Mehta V (2020) | 0.38 (0.23, 0.54) | 6.17 |
| Lievre A (2020) | 0.31 (0.27, 0.35) | 18.69 |
| Dai MY (2020) | 0.11 (-0.01, 0.22) | 11.13 |
| Zhang HY (2020) | 0.35 (0.14, 0.56) | 5.33 |
| Bhangu MA (2020) | 0.19 (0.10, 0.28) | 13.82 |
| Subtotal (I-squared = 71.5%, p = 0.004) | 0.25 (0.17, 0.33) | 66.99 |
| Multicenter | Lee LLY (2020) | 0.28 (0.21, 0.35) | 15.52 |
| Liu YL (2020) | 0.17 (-0.13, 0.46) | 3.01 |
| Yang F (2020) | 0.13 (-0.04, 0.29) | 7.58 |
| Yu J (2020) | 0.33 (0.20, 0.87) | 1.04 |
| Nakamura S (2020) | 0.15 (-0.04, 0.35) | 5.85 |
| Subtotal (I-squared = 5.0%, p = 0.378) | 0.24 (0.17, 0.30) | 33.01 |
| Overall (I-squared = 55.7%, p = 0.012) | 0.24 (0.18, 0.30) | 100.00 |

**NOTE:** Weights are from random effects analysis.
3.4. Publication bias

A funnel plot of the selected studies is shown in Figure 6. The plot was symmetrical on visual inspection, suggesting a low risk of publication bias.

4. Discussion

COVID-19 has become a threat to global health care because of its high infectivity and human-to-human transmission. Cancer patients are usually characterized by older age, impaired immune system, and a variety of chronic diseases (such as coronary heart disease, hypertension, chronic obstructive pulmonary disease, and diabetes), which places them at high risk of being infected by COVID-19.[22] During the pandemic, the management mode of cancer patients was forced to be adjusted in many aspects. Telemedicine was advocated instead of face-to-face consultation, and intravenous chemotherapy was shifted to oral chemotherapy to reduce the potential risk of hospital-acquired infection.[22–24]

A recent meta-analysis conducted by Cao et al showed that the CFR of COVID-19 in the general population was 6.8% (CI, 0.04–0.09),[25] while a single-center retrospective study by Ma et al found that the mortality rate of COVID-19 in cancer patients was 13.5%.[26] Yang et al analyzed the clinical characteristics of patients with COVID-19 in Hubei, China, and found that the mortality rates of lung cancer, breast cancer, and thyroid cancer were 25%, 7.5%, and 6.25%, respectively.[10] It is well known that digestive system tumors are the second leading cause of cancer-related deaths. According to the 2018 Global Cancer Statistics Report released by the World Health Organization, the mortality rates of colorectal cancer, gastric cancer, and liver cancer were 9.2%, 8.2%, and 8.2%, respectively.[27] However, against the current background of viral epidemics, the impact of COVID-19 on the prognosis of patients with digestive system tumors has rarely been studied. In our systematic review and meta-analysis, we observed that the overall mortality of patients with digestive system tumors and COVID-19 was 24%, which was much higher than the mortality rate reported in the 2018 Global Cancer Statistics.

In the clinical practice of gastrointestinal tumors, the COVID-19 pandemic has put incredible pressure on the screening and
diagnostic procedures for gastrointestinal tumors. Similar to chemotherapy, radiotherapy, and targeted therapy, surgery can also lead to systemic immunosuppression. Patients with cancer undergoing surgery are more susceptible to various bacterial and viral infections than the general population.[28-29] On March 13, 2020, the American College of Surgeons recommended minimizing, postponing, or canceling elective surgery during a pandemic.[8] To reduce the risk of virus exposure, difficult cases cannot be discussed by a multidisciplinary team, and many non-advanced patients lose the opportunity for follow-up surgery because they cannot receive neoadjuvant radiotherapy and chemotherapy.

In addition to emergency endoscopic surgery, endoscopy in non-emergency situations has been postponed or even suspended in many countries and regions. In Italy, 49 of 121 hospitals (47%) suspended their endoscopic screening programs for colorectal cancer during the COVID-19 pandemic.[10] In North America, colonoscopy was delayed in 71 (97%) of 73 digestive endoscopy centers.[31] In Hong Kong, the number of endoscopies decreased by more than 50%, resulting in a 49.1% and 38.1% decrease in the diagnostic rate of gastric cancer and colorectal cancer, respectively.[17] This is alarming, with the number of delayed examinations increasing every day, which may lead to saturation of the digestive department at the end of the pandemic, and the consequences for patients cannot be recovered from the accumulated delays. European guidelines for quality assurance in colorectal cancer screening and diagnosis recommend colonoscopy within one month of a positive fecal occult blood test.[32] When colonoscopy is delayed for more than 6 months, the risk of advanced colorectal cancer with distant metastasis is high.[33] It can be predicted that the longer the lag time, the more advanced the lesions and the higher the mortality of tumor patients (far more than 24%).

Holshue et al confirmed for the first time that SARS-CoV-2 is present in the patient’s feces.[134] Subsequently, Zhang et al proposed that coronaviruses may be transmitted through the fecal-oral route.[33] Studies have successively reported that the viral RNA test results in the stool samples of COVID-19 patients ranged from 6.5% to 66.67%.[136-138] This clinical evidence indicates that the intestine may be another important target organ for SARS-CoV-2.

Hoffmann et al proved that SARS-CoV-2 binds to the angiotensin-converting enzyme-2 (ACE-2) receptor, enters the endoplasmic body of the host cell, and is cleaved and activated by cathepsin L (CTSL). In addition, transmembrane protease serine 2 (TMPRSS2) and ACE-2 are co-expressed on the cell membrane and can stimulate spike viral proteins, thereby activating the fusion of the virus with the membrane lipid layer and promoting its entry into host cells. Therefore, the coronavirus receptors ACE2 and TMPRSS2 have been considered to play a key role in SARS-CoV-2 infected cells.[139]

Wang et al evaluated the expression of infection core genes ACE2 and TMPRSS2 in different types of cancer using the GEPIA database and found that the mRNA expression of ACE2 and TMPRSS2 in colorectal cancer was higher than that in other types of cancer.[40] Liu et al found coronavirus-like particles in the cytoplasm or surface of enterocytes from the appendix, colon, or rectum of 5 patients and confirmed considerable ACE2 expression in SARS-CoV-2 infected enterocytes by immunofluorescence and fluorescent ISH. This is the first report to show the presence of active SARS-CoV-2 in the appendix, colon, and rectum of an infected patient.[8] ACE2 was highly expressed not only in the absorptive enterocytes from the colon, but also in stratified epithelial cells of the upper esophagus. Guan et al also detected SARS-CoV-2 in cases of esophageal erosion and in the bleeding sites of patients with peptic ulcer.[51] These results may explain why SARS-CoV-2 can be isolated from feces and spread through the fecal-oral route.

From another perspective, SARS-CoV-2 may contribute to the deterioration of tumor patients. Related pathophysiological studies have found that SARS-CoV-2 infection is characterized by continuous activation of T cells leading to a state of exhaustion,[42,43] which leads to a weakened cellular immune response necessary for COVID-19 patients to effectively eliminate the virus. Therefore, in laboratory examinations, many patients show lymphopenia.[44-46] Cytokine release syndrome is an important aggravating mechanism of COVID-19. SARS-CoV-2 induces self-injury of tissues and organs through excessive production of pro-inflammatory cytokines.[47,48] The potential immunosuppressive microenvironment caused by abnormal immune cell functions is an important pathogenesis of malignant tumors.[49] In addition, advanced age, multiple comorbidities, radiotherapy, chemotherapy, and other cytotoxic treatments have led to further damage to the immune system of cancer patients. When faced with additional insults (such as COVID-19), cancer patients may not have enough immunity to fight the infection. As the pandemic progresses, cancer populations show more severe cases.

Huang et al reported the clinical characteristics of 41 confirmed patients in Wuhan for the first time. In addition to typical respiratory symptoms, patients have various degrees of gastrointestinal dysfunction.[30] A systematic literature review on the digestive system manifestations of COVID-19 reported that about 3% to 40.7% of patients have gastrointestinal symptoms, manifesting as nausea, diarrhea, anorexia, vomiting, abdominal pain, belching, bloating, and gastrointestinal bleeding.[41] Further pathological studies revealed that in infected patients with gastrointestinal symptoms, the digestive system will have a series of manifestations such as necrosis, atrophy, congestion, hemorrhage, and infarction.[51] In the process of clinical diagnosis and treatment, many cases initially showed atypical respiratory symptoms such as nausea and diarrhea, leading to delayed diagnosis. This also contributed to the poor prognosis of patients with gastrointestinal cancer to a certain extent.

It is necessary to make adjustments for the current crisis of patients with gastrointestinal cancer. Under the premise of fully complying with the international guidelines to limit the spread of COVID-19, we call for the resumption of endoscopic screening programs and selective surgery as soon as possible. Multi-target stool fecal immunochemical test (FIT)-DNA detects DNA mutations in fecal exfoliated cells. This is combined with a FIT to form an individual comprehensive risk score. Subjects whose comprehensive score exceeds a preset threshold are defined as high-risk groups and require colonoscopy. A prospective validation study involving 9989 subjects conducted in the United States and Canada reported that the sensitivity of this multi-target stool FIT-DNA test for colorectal cancer and advanced adenoma was 92.3% and 42.4%, respectively.[52] Based on this research, this detection technology has been approved by the U.S. Food and Drug Administration and recommended by the U.S. Colorectal Cancer Screening Guidelines for colorectal cancer screening. At present, China also has multi-target FIT-DNA testing products approved by the
the research data we included may not be able to re-
cancer. With the rapid development and spread of the pandemic,
characteristics of mortality in patients with gastrointestinal
further explore whether these covariates are consistent with the
cancer, have a higher
correlation between the clinical characteristics and prognosis of
were not comprehensive enough, we did not further analyze the
corresponding regions that do not have the conditions for open endoscopic
screening and surgery, and this will lead to a series of
digestive tract tumors to a certain degree. Vaccination is the most
effective way to prevent and control the COVID-19 pandemic. A
variety of 2019-nCoV vaccines produced in China have been
certified by the WHO for safety, effectiveness, and quality,
providing more options and powerful weapons for controlling the
global epidemic as soon as possible.

Our study had some limitations. Because the collected data
were not comprehensive enough, we did not further analyze the correlation between the clinical characteristics and prognosis of cancer patients. Many studies have reported that elderly patients, men, and those with comorbidities, such as hypertension, chronic lung disease, diabetes, and cancer, have a higher incidence and mortality risk. We encourage future researchers to further explore whether these covariates are consistent with the characteristics of mortality in patients with gastrointestinal cancer. With the rapid development and spread of the pandemic, the research data we included may not be able to reflect the actual situation of infection and mortality in real time because our research data came from different countries and regions in the world. Moreover, it is unclear if the deaths are caused by COVID-19 or cancer. Some patients who died out of the hospital or had an asymptomatic infection may be missed, resulting in high or low mortality. Therefore, the combined mortality we obtained should be interpreted with caution (Supplemental Table, original material of Table 1.xlsx, http://links.lww.com/MD2/B48).

In conclusion, the COVID-19 pandemic has caused tremendous and profound changes in the diagnosis and treatment of gastrointestinal cancers. The fatality rate of patients with gastrointestinal tumors is increasing with the delay of endoscopic screening and surgery, and this will lead to a series of unpredictable consequences. Therefore, the relevant public health centers should formulate a standardized and active restart plan to actively respond to the huge challenges posed by COVID-19 within a controllable range and, to a certain extent, balance the adverse effects of this vulnerable group due to delays in diagnosis and treatment.

Author contributions

Conceptualization: Wensen Chen, Xiaofeng Chen.
Data curation: Guoqun Wang, Lanlan Pan, Jianyi Zhao.
Formal analysis: Wensen Chen, Xiaofeng Chen, Yueyu Fang, Hui Sun, Jie Tang.
Investigation: Guoqun Wang, Lanlan Pan.
Methodology: Wensen Chen.
Project administration: Wensen Chen.

Resources: Guoqun Wang.
Software: Guoqun Wang, Wensen Chen.
Supervision: Wensen Chen, Xiaofeng Chen.
Validation: Wensen Chen.
Writing – original draft: Guoqun Wang.
Writing – review & editing: Guoqun Wang, Wensen Chen, Xiaofeng Chen, Poshita Kumari Seesaha.

References

[1] Li Q, Guan XH, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199–207.
[2] Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335–7.
[3] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China Summary of a Report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239–42.
[4] Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;369:m1091.
[5] Wang DW, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.
[6] Garassino MC, Whisenant JG, Huang L-C, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 2020;21:914–22.
[7] Lui TKL, Leung K, Guo CG, Tsui VWM, Wu JT, Leung WK. Impacts of the coronavirus 2019 pandemic on gastrointestinal endoscopy volume and diagnosis of gastric and colorectal cancers: a population-based study. Gastroenterology 2020;159:1164–6. e5.
[8] Liu Y-L, Ren J, Yuan J-F, et al. Postoperative onset and detection of SARS-CoV-2 in surgically resected specimens from gastrointestinal cancer patients with/without asymptomatic COVID-19. Ann Surg 2020;272: E321–8.
[9] Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively infects human gut enterocytes. Science 2020;369:50–4.
[10] Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21:904–13.
[11] Lee LYW, Cozier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 2020;21:1309–16.
[12] Mehta V, Goel S, Kabariti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov 2020;10:935–41.
[13] Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol 2020;92:2067–73.
[14] Pinto C, Berselli A, Mangone L, et al. SARS-CoV-2 positive hospitalized cancer patients during the Italian Outbreak: the cohort study in Reggio Emilia. Biol-Basel 2020;9.
[15] Lievre A, Turpin A, Ray-Coquard I, et al. Risk factors for coronavirus disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19). Eur J Cancer 2020;14:62–81.
[16] Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 2020;10:783–91.
[17] Zhang H, Wang L, Chen Y, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer 2020;126:4023–31.
[18] Stroppa EM, Toscani I, Citterio C, et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future Oncol 2020;16:1425–32.
[19] Bhangoo A, Collaborative CO. Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic. Colorectal Dis 2021;23:732–49.
[20] Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a Tertiary Care hospital in Wuhan, China. JAMA Oncol 2020;6:1108–10.

[21] Nakamura S, Kanemasa Y, Atsuta Y, et al. Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan. Int J Clin Oncol 2021;26:485–93.

[22] Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020;395:1919–26.

[23] Banna G, Curioni-Fontecedro A, Friedlaender A, Addeo A. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere. Esmo Open 2020;5:e000765.

[24] Ribal MJ, Cornford P, Briganti A, et al. European Association of Urology Guidelines Office Rapid Reaction Group: an organisation-wide collaborative effort to adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. Eur Urol 2020;78:21–8.

[25] Afshar ZM, Dayani M, Naderi M, Ghanbarveisi F, Shiri S, Rajati F. Guidelines Of Fi eR a p i dR e a c ti o nG r o u p : a no rganisation-wide collabora-

[26] Ma J, Yin J, Qian Y, Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: a single-center’s retrospective study. J Infect 2020;81:E114–6.

[27] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

[28] Menger MD, Vollmar B. Surgical trauma: hyperinflammation versus immunosuppression? Langenbecks Arch Surg 2004;389:475–84.

[29] Rolston KVI. The spectrum of pulmonary infections in cancer patients. Curr Oncol 2001;13:218–23.

[30] Maeda M, Serrazza S, Savarino E, et al. Impact of the COVID-19 pandemic on Gastroenterology Divisions in Italy: a national survey. Dig Liver Dis 2020;52:808–15.

[31] Forbes N, Smith ZL, Spitzer RL, et al. Changes in gastroenterology and inflammation versus immunosuppression? Langenbecks Arch Surg 2004;389:475–84.

[32] Moss S, Ansell-Park R, Brenner H. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition Evaluation and interpretation of screening outcomes. Endoscopy 2012;44: SE49–64.

[33] Lee YC, Fann JC, Chiang TH, et al. Time to colonoscopy and risk of colorectal cancer in patients with positive results from fecal immunochemical tests. Clin Gastroenterol Hepatol 2019;17:1332–40. e3.

[34] Holshue ML, DeBolt C, Lindquist S, et al. First case of novel coronavirus in the United States. N Engl J Med 2020;382:929–36.

[35] Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020;9:386–9.

[36] Gupta S, Parker J, Smits S, Underwood J, Dolwani S. Persistent viral shedding of SARS-CoV-2 in faeces: a rapid review. Colorectal Dis 2020;22:611–20.

[37] Kipkorir V, Cheruiyot I, Ngure B, Misiani M, Munguti J. Prolonged SARS-CoV-2 RNA detection in anal/rectal swabs and stool specimens in COVID-19 patients after negative conversion in nasopharyngeal RTPCR test. J Med Virol 2020;92:3238–31.

[38] Chen YF, Chen LJ, Deng QL, et al. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol 2020;92:833–40.

[39] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271–80.

[40] Wang B, Huang Y. Which type of cancer patients are more susceptible to the SARS-COX-2: evidence from a meta-analysis and bioinformatics analysis. Crit Rev Oncol Hematol 2020;153:103032.

[41] Ye L, Yang Z, Liu J, Liao L, Wang F. Digestive system manifestations and clinical significance of coronavirus disease 2019: a systematic literature review. J Gastroenterol Hepatol 2021;36:1414–22.

[42] Gardhane SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med 2020;217:e20200678.

[43] Jiang M, Guo Y, Luo Q, et al. T-cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of coronavirus disease 2019. J Infect Dis 2020;222:198–202.

[44] Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71:762–8.

[45] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.

[46] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–81.

[47] Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4.

[48] Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020;368:473–4.

[49] Menter T, Tzankov A. Mechanisms of immune evasion and immune Modulation by Lymphoma Cells. Front Oncol 2018;8:54.

[50] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

[51] Chen B, Tian EK, He B, et al. Overview of lethal human coronaviruses. Signal Transduct Target Ther 2020;5:89.

[52] Imperiale TF, Ramshoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287–97.

[53] National Cancer Center CEGoTDoC, Guideline for the Screening ED, Early Treatment o, Colorectal CChina Guideline for the screening, early detection and early treatment of colorectal cancer (2020, Beijing). Bull Chin Cancer 2021;30:1–28.